Halozyme Therapeutics (NASDAQ:HALO) Updates FY24 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $3.55-3.90 for the period, compared to the consensus earnings per share estimate of $3.52. The company issued revenue guidance of $915-985 million, compared to the consensus revenue estimate of $954.43 million.

Halozyme Therapeutics Stock Down 1.5 %

HALO traded down $0.67 on Friday, reaching $43.17. 329,127 shares of the company traded hands, compared to its average volume of 1,210,315. The stock’s 50 day moving average price is $40.17 and its 200-day moving average price is $38.05. Halozyme Therapeutics has a 52-week low of $31.86 and a 52-week high of $45.00. The company has a market cap of $5.48 billion, a price-to-earnings ratio of 20.78, a PEG ratio of 0.47 and a beta of 1.26. The company has a debt-to-equity ratio of 17.89, a current ratio of 6.64 and a quick ratio of 5.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The firm had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. On average, sell-side analysts expect that Halozyme Therapeutics will post 3.43 EPS for the current fiscal year.

Analyst Ratings Changes

HALO has been the subject of several research analyst reports. JMP Securities cut their target price on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a market outperform rating for the company in a research note on Wednesday. TheStreet lowered shares of Halozyme Therapeutics from a b- rating to a c+ rating in a report on Monday, January 22nd. HC Wainwright reiterated a buy rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday. Benchmark restated a buy rating and set a $50.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday, April 16th. Finally, The Goldman Sachs Group cut their target price on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a neutral rating on the stock in a research report on Thursday, January 18th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics has a consensus rating of Moderate Buy and an average price target of $53.14.

Insider Buying and Selling

In other news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $38.49, for a total transaction of $384,900.00. Following the completion of the transaction, the senior vice president now directly owns 168,176 shares of the company’s stock, valued at approximately $6,473,094.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders sold 30,000 shares of company stock valued at $1,196,800. 2.70% of the stock is owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.